-
-
-
-
-
-
-
NewAmsterdam Pharma Co NV (NAMS) PT Raised to $55 at Leerink Partners
-
-
-
-
-
-
-
EMA accepts NewAmsterdam obicetrapib applications for review
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on NewAmsterdam Pharma Co NV (NAMS)
-
-
-
-
-
-
-
NewAmsterdam Pharma Co NV (NAMS) PT Raised to $52 at Scotiabank
-
-
-
-
-
-
-
NewAmsterdam Pharma (NAMS) Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on NewAmsterdam Pharma Co NV (NAMS)
-
-
-
416,816 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

